Morphic Medical
Innovative therapies for type 2 diabetes and obesity, rooted in excellence since 2003.
Innovative therapies for type 2 diabetes and obesity, rooted in excellence since 2003.
Morphic Medical, formerly known as GI Dynamics Inc., is a pioneer in developing innovative therapies for type 2 diabetes and obesity. The company's flagship product, RESET® (EndoBarrier), is an endoscopically delivered device therapy that provides a non-surgical alternative for treating type 2 diabetes and obesity. It is important to note that RESET is currently limited to investigational use only and is not approved for sale in the United States. Founded in 2003, Morphic Medical is based in Boston, Massachusetts, and operates within the Biotechnology, Health Care, Health and Wellness, and Medical Devices sectors. In August 2019, the company secured a significant $10.00M Post-IPO Equity investment from Crystal Amber. The focus on non-surgical therapies for type 2 diabetes and obesity positions Morphic Medical as an emerging player in the healthcare innovation space, with potential for impactful growth and value creation.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $10.00M | 1 | Crystal Amber | 23 Aug 2019 |
| Post-IPO Equity | $5.00M | - | 20 Sep 2018 | |
| Post-IPO Equity | $1.80M | - | 08 May 2018 | |
| Post-IPO Equity | $2.05M | - | 22 Jan 2018 | |
| Post-IPO Debt | $5.00M | - | 15 Jun 2017 |
No recent news or press coverage available for Morphic Medical.
We care about your data, and we'd love to use cookies make your experience better.
